Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: Sclerostin, an osteocyte secreted protein encoded by SOST gene, is an important regulator of Wnt pathway. It prevents bone formation by blocking Wnt binding to its receptor. High levels of sclerostin have been reported in post-menopausal women with osteoporosis. Sclerostin can be induced during inflammation and may also inhibit repair of bone erosion in patients with rheumatoid arthritis (RA). There are few studies demonstrating the role of sclerostin on bone mass and disease activity in RA patients. This study aims to assess the serum sclerostin level in patients with RA and to correlate its level with disease activity and bone mineral density.
Methods: Forty-seven patients of RA fulfilling the ACR/EULAR (2010) criteria, attending the department of Rheumatology, King George Medical University, Lucknow, India were included in the study. Twenty-eight age- and sex-matched healthy controls were enrolled from the same geographic area. Apart from routine blood investigations; rheumatoid factor (RF), anti citrullinated protein antibody (ACPA), 25 hydroxy vitamin D, radiographs and bone mineral density (BMD) were also done. Disease activity was assessed by CDAI. Serum sclerostin levels of both cases and controls was assayed by using enzyme-linked immunosorbent assay (ELISA) assay [Elabscience, coefficient of variation (CV) < 10%] and compared with disease activity and bone mineral density.
Results: Mean age of RA patients was 32.7+6.8 yrs with mean duration of disease 4.2+2 yrs. Mean age of the control group was 28.7+6.3 yrs. Rheumatoid factor was positive in 29 out of 38 patients and anti citrullinated protein antibody was positive in 44 out of 47 patients. Mean sclerostin level among patients was 8422+3655 and that of control group was 6479+1510 (p value 0.002). Serum sclerostin level did not correlate significantly with ESR (r:-0.31, p:0.048), CRP (r:-0.11, p:0.65), CDAI (r:-0.11, p:0.45), BMD at lumbar spine(L1-4, r:.14, p:0.35) and femur (r:0.06, p: 0.67).
Conclusion: Serum sclerostin level did not correlate with disease activity and BMD in RA patients.
To cite this abstract in AMA style:Sahoo RR Sr., Dhakad U, Das SK, Srivastava R, Tripathy SR, Srivastava D, Velayudhan H. Serum Sclerostin Levels in Rheumatoid Arthritis (RA) and Its Correlation with Disease Activity and Bone Mineral Density [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/serum-sclerostin-levels-in-rheumatoid-arthritis-ra-and-its-correlation-with-disease-activity-and-bone-mineral-density/. Accessed December 2, 2020.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-sclerostin-levels-in-rheumatoid-arthritis-ra-and-its-correlation-with-disease-activity-and-bone-mineral-density/